Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the safety and efficacy of RF ablation using the Intracept Intraosseous Nerve Ablation System to ablate intraosseous nerves for the relief of chronic axial low back pain. This is a prospective, double-blind, randomized, sham-controlled clinical trial with an optional crossover component.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intracept Treatment | Experimental |
| |
| Sham Treatment | Sham Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intracept Treatment | Device | Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in ODI From Baseline to 3 Months Post-treatment | The primary variable is the Oswestry Disability Index (ODI) and the primary efficacy endpoint is the mean improvement from baseline to 3 months in the ODI. The primary endpoint will be evaluated in both the treatment and sham groups with between-group comparisons used to assess the success of the Intracept System in reducing chronic axial low back pain. ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Patient Success at 3 Months | Proportion of subjects with clinical success at 3 months, where clinical success was defined as:
|
Not provided
Inclusion Criteria:
Skeletally mature patients age 25 - 70 years, inclusive
Chronic lower back pain for at least six (6) months
Failure to respond to at least six (6) months of non-operative conservative management. The minimum requirement is as follows:
Oswestry Disability Index (ODI) at time of evaluation of at least 30 points
Baseline Visual Analog Scale (VAS) of at least 4cm on a 10cm scale
The following test indicating that the vertebral body is the source of pain:
1.MRI showing Type 1 or Type II Modic changes at least one vertebral endplate, at one or more levels from L3 to S1
Understands the local language and is willing and able to follow the requirements of the protocol
Understands the informed consent and signs the institutional review board/ independent ethics committee (IRB/IEC) approved informed consent form
Exclusion Criteria:
Radicular pain by history or evidence of pain or neurological deficit in a dermatomal zone at or below the medial thigh.
Previous surgery performed on the lumbar spine
History of symptomatic spinal stenosis
History of osteoporotic or tumor-related vertebral body compression fracture
History of vertebral cancer or spinal metastasis
History of spinal infection
Metabolic bone disease (e.g. osteogenesis imperfecta)
BMI ≥40
Osteoporosis, defined as T score <-2.5
Any radiographic evidence of other important back pathology, such as:
MRI evidence of Modic changes, Type I or Type II at greater than 3 vertebral bodies.
Any back pathology related to trauma, evidence of vertebral compression fracture or other spinal pathology that could affect assessment of response to back pain
Demonstrates 3 or more Waddell's signs of Inorganic Behavior
Any evidence of current systemic infection
Uncorrected bleeding diathesis
Any neurologic problem that prevents early mobilization after surgery or interferes with assessment of ODI
Contraindication to MRI or patients who have allergies to the components of the Intracept device
Pregnant, lactating or plan to become pregnant in next year
Diabetes requiring daily insulin
Current use of steroid therapy, with the exception of inhalation steroids for asthma
Evidence of mental instability or uncontrolled depression; patients requiring anti-depressants or anti-psychotics within 3 months of enrollment are not eligible; patients with a Beck Depression Score of greater than 24 are not eligible
Receiving Workmen's Compensation
Currently involved in litigation regarding back pain/injury or financial incentive to remain impaired
Any medical condition that impairs follow-up
Contraindications to the proposed anesthetic protocol.
Evidence of substance abuse; patients using prescribed extended release narcotics are not eligible (e.g. fentanyl patch,MS contin, oxycontin)
Known to require at the time of screening and/or randomization, additional surgery to the lumbar spinal region within six months
Being treated with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone use up to 5 mg/qd or its equivalent is allowed)
Has a life expectancy of less than 1 year
Has active implantable devices, such as cardiac pacemakers, spinal cord stimulators, etc.
Is a prisoner
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jeffrey Fischgrund, MD | Michigan Orthopaedic Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Desert Institute for Spine Care | Phoenix | Arizona | 85020 | United States | ||
| SpineCare Medical Group |
2:1 Randomization (treatment: sham)
Subjects were screened and enrolled at 15 sites in the US and 3 sites in Germany
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Intracept Treatment | Intracept Treatment: Percutaneous access and RF ablation of the basivertebral nerve within the lumbar vertebral body to treat chronic axial low back. |
| FG001 | Sham Treatment |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sham Treatment | Device | Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered. |
|
| 3 months |
| Change in ODI From Baseline to 6 Months Post-treatment | The improvement in ODI at 6 months compared to baseline. ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms. | 6 months |
| Daly City |
| California |
| 94015 |
| United States |
| Memorial Orthopedic Surgical Group | Long Beach | California | 90806 | United States |
| The Spine Institute | Santa Monica | California | 90403 | United States |
| Pain Center Solutions | Marietta | Georgia | 30060 | United States |
| Indiana Spine Group | Carmel | Indiana | 46032 | United States |
| Maine Medical Partners | Scarborough | Maine | 04074 | United States |
| Partners in Research and Educational Studies of Spinal Disorders (PressD) | Southfield | Michigan | 48033 | United States |
| OrthoCarolina | Charlotte | North Carolina | 28207 | United States |
| NeuroSpine Institute | Eugene | Oregon | 97401 | United States |
| Rothman Institute | Philadelphia | Pennsylvania | 19107 | United States |
| Seton Spine & Scoliosis Center | Austin | Texas | 78731 | United States |
| Virginia iSpine Physicians | Richmond | Virginia | 23235 | United States |
Sham Treatment: Percutaneous access to the lumbar vertebra, no RF ablation delivered.
| 3 Month Follow-up |
|
| 6 Month Follow-up |
|
| 12 Month Follow-up |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Intent to Treat Population
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Intracept Treatment | Intracept Treatment: Percutaneous access and RF ablation of the basivertebral nerve within the lumbar vertebral body to treat chronic axial low back. |
| BG001 | Sham Treatment | Sham Treatment: Percutaneous access to the lumbar vertebra, no RF ablation delivered. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Gender | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||||
| Oswestry Disability Index (ODI) | ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms. | Mean | Standard Deviation | units on a scale |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in ODI From Baseline to 3 Months Post-treatment | The primary variable is the Oswestry Disability Index (ODI) and the primary efficacy endpoint is the mean improvement from baseline to 3 months in the ODI. The primary endpoint will be evaluated in both the treatment and sham groups with between-group comparisons used to assess the success of the Intracept System in reducing chronic axial low back pain. ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms. | Per Protocol Population: subjects that received the intended therapy per randomization assignment (appropriate ablation of the basivertebral nerve in the Intracept System arm) and completed follow-up per the study protocol. | Posted | Least Squares Mean | 95% Confidence Interval | units on a scale | 3 months |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Patient Success at 3 Months | Proportion of subjects with clinical success at 3 months, where clinical success was defined as:
| Per Protocol Population: subjects that received the intended therapy per randomization assignment (appropriate ablation of the basivertebral nerve in the Intracept System arm) and completed follow-up per the study protocol. | Posted | Number | percentage of patients | 3 months |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change in ODI From Baseline to 6 Months Post-treatment | The improvement in ODI at 6 months compared to baseline. ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms. | Per Protocol Population: subjects that received the intended therapy per randomization assignment (appropriate ablation of the basivertebral nerve in the Intracept System arm) and completed follow-up per the study protocol. | Posted | Least Squares Mean | 95% Confidence Interval | units on a scale | 6 months |
|
|
12 Months
Adverse Events reported for all Intent to Treat subjects from randomization through 12 months of follow-up
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Intracept Treatment | Intracept Treatment: Percutaneous access and RF ablation of the basivertebral nerve within the lumbar vertebral body to treat chronic axial low back. | 9 | 147 | 78 | 147 | ||
| EG001 | Sham Treatment | Sham Treatment: Percutaneous access to the lumbar vertebra, no RF ablation delivered. | 5 | 78 | 24 | 78 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Gastrointestinal bacterial infection | Infections and infestations | MedDRA Version 14.1 | Not related to device or procedure |
| |
| Airway obstruction on anaesthetic induction | Injury, poisoning and procedural complications | MedDRA Version 14.1 | Procedure related |
| |
| Complications from lymph node excision | Injury, poisoning and procedural complications | MedDRA Version 14.1 | Not related to device or procedure |
| |
| Arthritis aggravated | Musculoskeletal and connective tissue disorders | MedDRA Version 14.1 | Not related to device or procedure |
| |
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA Version 14.1 | Not related to device or procedure |
| |
| Low back pain | Musculoskeletal and connective tissue disorders | MedDRA Version 14.1 | Not related to device or procedure |
| |
| Grand mal seizure | Nervous system disorders | MedDRA Version 14.1 | Not related to device or procedure |
| |
| CVA | Nervous system disorders | MedDRA Version 14.1 | Not related to device or procedure |
| |
| C-section | Surgical and medical procedures | MedDRA Version 14.1 | Not related to device or procedure |
| |
| Hip replacement | Surgical and medical procedures | MedDRA Version 14.1 | Not related to device or procedure |
| |
| Bladder operation | Surgical and medical procedures | MedDRA Version 14.1 | Not related to device or procedure |
| |
| Deep vein thrombosis | Vascular disorders | MedDRA Version 14.1 | Not related to device or procedure |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Incision site discomfort | Injury, poisoning and procedural complications | MedDRA Version 14.1 |
| ||
| Leg pain | Musculoskeletal and connective tissue disorders | MedDRA Version 14.1 |
| ||
| Low back pain | Musculoskeletal and connective tissue disorders | MedDRA Version 14.1 |
| ||
| Post procedural nausea | Injury, poisoning and procedural complications | MedDRA Version 14.1 |
|
Individual PIs will not publish any study results until completion of study and publication of the multi-center results in a peer-reviewed journal, which shall occur within one year after study completion. Thereafter, PIs may publish individual site experience. Sponsor can review results communications prior to public release and can embargo communications regarding results for a period that is less than or equal to 60 days from the time submitted to sponsor for review.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| V.P. of Clinical & Regulatory Affairs | Relievant Medsystems, Inc. | 650-261-2259 | lhook@relievant.com |
| ID | Term |
|---|---|
| D017116 | Low Back Pain |
| ID | Term |
|---|---|
| D001416 | Back Pain |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| >=65 years |
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Germany |
|
| Participants |
|
|
| Participants |
|
|